NVNO
enVVeno Medical Corporation
Medical - Devices
Market Cap$7M
5Y Perf.+22.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NVNO vs VNRX
Revenue, margins, valuation, and 5-year total return — side by side.
VNRX
VolitionRx Limited
Medical - Diagnostics & Research
Market Cap$12M
5Y Perf.-96.3%
NVNO vs VNRX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NVNO | VNRX |
|---|---|---|
| Industry | Medical - Devices | Medical - Diagnostics & Research |
| Market Cap | $7M | $12M |
| Revenue (TTM) | $0.00 | $2M |
| Net Income (TTM) | $-19M | $-23M |
| Gross Margin | — | 100.0% |
| Operating Margin | — | -12.5% |
| Total Debt | $700K | $11M |
| Cash & Equiv. | $3M | $1M |
NVNO vs VNRX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NVNO
VNRX
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| enVVeno Medical Cor… (NVNO) | 100 | 122.0 | +22.0% |
| VolitionRx Limited (VNRX) | 100 | 3.7 | -96.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NVNO vs VNRX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NVNO leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. VolitionRx Limited is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
NVNO
enVVeno Medical Corporation
The Growth Play
NVNO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 97.9%
- -92.4% 10Y total return vs VNRX's -96.5%
- 2.3% margin vs VNRX's -13.5%
Best for: growth exposure and long-term compounding
VNRX
VolitionRx Limited
The Income Pick
VNRX is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.28
- Lower volatility, beta 0.28, current ratio 0.17x
- Beta 0.28, current ratio 0.17x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | VNRX | 40.0% revenue growth vs NVNO's 12.0% |
| Quality / Margins | NVNO | 2.3% margin vs VNRX's -13.5% |
| Stability / Safety | VNRX | Beta 0.28 vs NVNO's 2.02 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NVNO | +173.8% vs VNRX's -78.3% |
| Efficiency (ROA) | NVNO | -60.4% ROA vs VNRX's -305.6% |
NVNO vs VNRX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2019
Segment breakdown not available.
NVNO vs VNRX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNVNOLAGGINGVNRX
VNRXVolitionRx Limited
1leads
NVNOenVVeno Medical Corpo…
3leads
6 Total Categories
CATEGORYLEADERvs VNRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NVNO1/1
Valuation MetricsMultiples, price ratios, and targets
VNRX1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NVNO3/4
Total Returns1Y, 3Y, 5Y total returns with dividends
NVNO6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NVNO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
VNRX and NVNO operate at a comparable scale, with $2M and $0 in trailing revenue.
| Metric | NVNOenVVeno Medical C… | VNRXVolitionRx Limited |
|---|---|---|
| RevenueTrailing 12 months | $0 | $2M |
| EBITDAEarnings before interest/tax | -$20M | -$20M |
| Net IncomeAfter-tax profit | -$19M | -$23M |
| Free Cash FlowCash after capex | -$15M | -$20M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | — | -12.5% |
| Net MarginNet income ÷ Revenue | — | -13.5% |
| FCF MarginFCF ÷ Revenue | — | -11.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +133.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +97.8% | +20.5% |
NVNO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
VNRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | NVNOenVVeno Medical C… | VNRXVolitionRx Limited |
|---|---|---|
| Market CapShares × price | $7M | $12M |
| Enterprise ValueMkt cap + debt − cash | $4M | $22M |
| Trailing P/EPrice ÷ TTM EPS | -0.30x | -0.51x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 6.97x |
| Price / BookPrice ÷ Book value/share | 0.22x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
VNRX leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
NVNO leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), VNRX scores 2/9 vs NVNO's 1/9, reflecting mixed financial health.
| Metric | NVNOenVVeno Medical C… | VNRXVolitionRx Limited |
|---|---|---|
| ROE (TTM)Return on equity | -66.4% | — |
| ROA (TTM)Return on assets | -60.4% | -3.1% |
| ROICReturn on invested capital | -47.3% | — |
| ROCEReturn on capital employed | -59.5% | — |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | 0.03x | — |
| Net DebtTotal debt minus cash | -$2M | $10M |
| Cash & Equiv.Liquid assets | $3M | $1M |
| Total DebtShort + long-term debt | $700,000 | $11M |
| Interest CoverageEBIT ÷ Interest expense | — | -8.44x |
NVNO leads this category, winning 3 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
NVNO leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NVNO five years ago would be worth $18,790 today (with dividends reinvested), compared to $371 for VNRX. Over the past 12 months, NVNO leads with a +173.8% total return vs VNRX's -78.3%. The 3-year compound annual growth rate (CAGR) favors NVNO at 39.8% vs VNRX's -61.7% — a key indicator of consistent wealth creation.
| Metric | NVNOenVVeno Medical C… | VNRXVolitionRx Limited |
|---|---|---|
| YTD ReturnYear-to-date | +2740.0% | -58.8% |
| 1-Year ReturnPast 12 months | +173.8% | -78.3% |
| 3-Year ReturnCumulative with dividends | +173.1% | -94.4% |
| 5-Year ReturnCumulative with dividends | +87.9% | -96.3% |
| 10-Year ReturnCumulative with dividends | -92.4% | -96.5% |
| CAGR (3Y)Annualised 3-year return | +39.8% | -61.7% |
NVNO leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NVNO and VNRX each lead in 1 of 2 comparable metrics.
Risk & Volatility
VNRX is the less volatile stock with a 0.28 beta — it tends to amplify market swings less than NVNO's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVNO currently trades 76.5% from its 52-week high vs VNRX's 12.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NVNOenVVeno Medical C… | VNRXVolitionRx Limited |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.02x | 0.28x |
| 52-Week HighHighest price in past year | $13.00 | $18.80 |
| 52-Week LowLowest price in past year | $0.30 | $0.27 |
| % of 52W HighCurrent price vs 52-week peak | +76.5% | +12.0% |
| RSI (14)Momentum oscillator 0–100 | 41.2 | 30.2 |
| Avg Volume (50D)Average daily shares traded | 13K | 714K |
Evenly matched — NVNO and VNRX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NVNOenVVeno Medical C… | VNRXVolitionRx Limited |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NVNO leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). VNRX leads in 1 (Valuation Metrics). 1 tied.
Best OverallenVVeno Medical Corporation (NVNO)Leads 3 of 6 categories
Loading custom metrics...
NVNO vs VNRX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — NVNO or VNRX?
Over the past 5 years, enVVeno Medical Corporation (NVNO) delivered a total return of +87.
9%, compared to -96. 3% for VolitionRx Limited (VNRX). Over 10 years, the gap is even starker: NVNO returned -92. 4% versus VNRX's -96. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — NVNO or VNRX?
By beta (market sensitivity over 5 years), VolitionRx Limited (VNRX) is the lower-risk stock at 0.
28β versus enVVeno Medical Corporation's 2. 02β — meaning NVNO is approximately 632% more volatile than VNRX relative to the S&P 500.
03Which is growing faster — NVNO or VNRX?
On earnings-per-share growth, the picture is similar: enVVeno Medical Corporation grew EPS 97.
9% year-over-year, compared to 29. 0% for VolitionRx Limited. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — NVNO or VNRX?
enVVeno Medical Corporation (NVNO) is the more profitable company, earning 0.
0% net margin versus -1352. 2% for VolitionRx Limited — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVNO leads at 0. 0% versus -1228. 6% for VNRX. At the gross margin level — before operating expenses — VNRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — NVNO or VNRX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is NVNO or VNRX better for a retirement portfolio?
For long-horizon retirement investors, VolitionRx Limited (VNRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
28)). enVVeno Medical Corporation (NVNO) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VNRX: -96. 5%, NVNO: -92. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between NVNO and VNRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NVNO is a small-cap quality compounder stock; VNRX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.